Best Value Stocks to Buy for May 9th
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 09 2025
0mins
Source: NASDAQ.COM
Top Stock Picks: Three stocks with strong value characteristics and a Zacks Rank #1 are highlighted for investors: Brenntag SE, Sumitomo Corporation, and Fresenius Medical Care AG, each showing positive earnings estimates and favorable price-to-earnings ratios compared to industry averages.
Investment Recommendations: Zacks Investment Research has released a report on the top 5 stocks likely to gain over 100% in the coming months, emphasizing one innovative financial firm with a rapidly growing customer base and promising solutions.
Analyst Views on FMS
Wall Street analysts forecast FMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is 25.00 USD with a low forecast of 22.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 22.330
Low
22.00
Averages
25.00
High
28.00
Current: 22.330
Low
22.00
Averages
25.00
High
28.00
About FMS
Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
